Sophie Gasperment
About Sophie Gasperment
Independent non-employee director at Cimpress plc since November 2016; age 61; current term expires at the 2026 AGM. She serves as Audit Committee member, Compensation Committee member, and Chair of the Nominating Committee; the Board met three times in FY2025 and each director attended every meeting of the Board and their committees during their service period. Background includes Senior Advisor to Boston Consulting Group (since November 2019) and senior leadership at L’Oréal, including Managing Director of L’Oréal UK & Ireland and Chair/Global CEO of The Body Shop. External public boards: Kingfisher plc (since December 2018) and Givaudan SA (since September 2020); prior boards include Accor (2010–2022; chaired Nomination/Remuneration/CSR) and D’Ieteren Group (2018–2023), plus an “expert in residence” role at Station F for HEC Paris (2019–2022). Independence: Yes under Nasdaq rules.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| L’Oréal | Multiple senior management roles, including Managing Director, L’Oréal UK & Ireland | 1986–2018 | Consumer brand-building and go-to-market leadership |
| The Body Shop (L’Oréal) | Chair and Global Chief Executive Officer | During L’Oréal tenure | Led values-led brand spanning 60 countries (~20,000 people at the time) |
| Boston Consulting Group | Senior Advisor (Consumer and Digital Acceleration) | Since Nov 2019 | Strategy support and digital transformation insights |
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Kingfisher plc (FTSE 100) | Director | Since Dec 2018 | Not specified in CMPR proxy |
| Givaudan SA | Director | Since Sep 2020 | Not specified in CMPR proxy |
| Accor | Director; Chair of Nomination/Remuneration/CSR Committee | 2010–2022 | Chaired nomination/remuneration/CSR |
| D’Ieteren Group | Director | 2018–2023 | Not specified in CMPR proxy |
| Station F (HEC Paris) | “Expert in residence” | Sep 2019–Jul 2022 | Start-up incubator engagement |
Board Governance
- Committee assignments (FY2025): Audit member; Compensation member; Nominating Chair; all committee members are independent. Meetings held: Audit (5), Compensation (4), Nominating (2). The Board met 3 times; each director attended every Board and committee meeting during their service period (100% attendance).
- Independence determination: All non-employee directors (including Ms. Gasperment) are independent under Nasdaq rules; Board conducts executive sessions of non-employee directors at least twice per year per guidelines.
- Compensation Committee interlocks: Ms. Gasperment served on the Compensation Committee in FY2025 alongside Dessislava Temperley and Scott Vassalluzzo (and former director Zachary Sternberg through Nov 2024); no relationships requiring disclosure for Ms. Gasperment. A related-party share repurchase involved entities affiliated with Mr. Vassalluzzo; disinterested Audit Committee members approved it under policy.
- Governance documents: Corporate Governance Guidelines, Code of Business Conduct, and committee charters are on IR website.
Fixed Compensation
| Component | Details | Vesting/Timing | FY2025 Amount (USD) |
|---|---|---|---|
| Annual cash retainer | $100,000 for all directors, paid quarterly and prorated for partial-year service | Ongoing | $100,000 (Gasperment) |
| Committee/Chair fees | Audit Committee Chair: +$25,000; no other chair fees disclosed | Ongoing | N/A for Gasperment (she chairs Nominating; no fee disclosed) |
| Meeting fees | Not disclosed | — | — |
| Director equity grant (RSUs) | $200,000 RSUs per fiscal year following the annual meeting; vest 25% per year over 4 years, prorated for new directors | 4-year vest, 25% per year | $199,947 grant-date fair value (Gasperment) |
Non-Employee Director Compensation (FY2025):
| Name | Fees Earned/Paid in Cash (USD) | Share Awards (USD) | Total (USD) |
|---|---|---|---|
| Sophie A. Gasperment | $100,000 | $199,947 | $299,947 |
Performance Compensation
- Outstanding director equity at June 30, 2025: Ms. Gasperment held 6,753 3YMA-based PSUs and 6,638 RSUs.
- 3YMA-based PSU design: PSUs pay out only if the three-year moving average share price achieves specified CAGR thresholds; multipliers range from 75% at 7% CAGR to 250% at ≥20% CAGR. To date, no shares have been issued under outstanding 3YMA-based PSUs as thresholds were not met; future issuances are unlikely absent a dramatic sustained increase in share price.
Key PSU Performance Mechanics:
| Measure | Threshold | Multiplier |
|---|---|---|
| 3YMA CAGR | 7% | 75% |
| 3YMA CAGR | ≥20% | 250% |
Note: Specific thresholds vary by award agreement; examples and footnotes for executives illustrate date- and CAGR-specific schedules, but director-specific PSU footnotes are not provided in the proxy.
Other Directorships & Interlocks
| Company | Relationship to CMPR | Potential Interlock/Conflict Notes |
|---|---|---|
| Kingfisher plc | Home improvement retail | No stated transactions with CMPR; minimal direct conflict risk disclosed |
| Givaudan SA | Flavors/fragrances | No stated transactions with CMPR; minimal direct conflict risk disclosed |
| Accor | Hospitality | Prior role; chaired Nom/Rem/CSR; no CMPR transactions disclosed |
| D’Ieteren Group | Diversified holdings | Prior role; no CMPR transactions disclosed |
Compensation Committee interlock context: Ms. Gasperment’s service on CMPR’s Compensation Committee coincided with a related-party share repurchase involving entities affiliated with fellow director Mr. Vassalluzzo; the disinterested Audit Committee members reviewed and approved under policy. No such relationships are attributed to Ms. Gasperment.
Expertise & Qualifications
- Leadership and strategy acumen from senior roles at L’Oréal and as Chair/Global CEO of The Body Shop; consumer brand-building, go-to-market expertise; insights in digital transformation from BCG advisory.
- International public company board experience (Kingfisher, Givaudan; prior Accor and D’Ieteren).
- Start-up ecosystem engagement (Station F “expert in residence” for HEC Paris).
Equity Ownership
| Item | Value |
|---|---|
| Beneficial ownership (Oct 16, 2025) | 5,281 shares; <1% outstanding |
| Near-term rights to acquire (within 60 days of Oct 16, 2025) | 2,611 shares (RSUs/PSUs/options) |
| Outstanding awards (Jun 30, 2025) | 6,638 RSUs; 6,753 3YMA-based PSUs |
| Ownership guidelines | Directors must hold ≥3x annual cash retainer; compliance: all directors satisfied or on track by Jun 30, 2025 |
| Hedging/derivatives policy | Prohibits hedging/derivative transactions (short sales, options, collars, futures, forwards, swaps) |
Governance Assessment
- Board effectiveness: 100% attendance; multi-committee engagement (Audit and Compensation), plus Nominating Chair role—strong participation signal.
- Independence & alignment: Independent director; standard director equity (RSUs) with multi-year vesting; legacy PSUs tied to share price growth reinforce pay-for-performance, though payouts have not occurred to date, limiting windfall risk.
- Ownership alignment: Beneficial stake with additional near-term issuable shares and adherence to 3x retainer ownership guideline; hedging prohibited—favorable alignment.
- Conflicts/related-party: No related-party transactions involving Ms. Gasperment; Committee interlock context managed via Audit Committee review for Prescott-related buyback—procedure adherence mitigates risk.
- Shareholder sentiment: Prior AGM (Dec 14, 2023) reappointed Ms. Gasperment; say-on-pay approved (non-binding).
Red Flags (none material disclosed specific to Ms. Gasperment):
- No pledging disclosed; hedging prohibited by policy.
- Multiple external boards raise potential bandwidth considerations, but attendance was 100% in FY2025.
Signals to monitor:
- Any changes to director compensation structure (e.g., adding chair fees beyond Audit Chair); currently, Nominating Chair does not have a disclosed fee.
- Evolving PSU/RSU practices for directors as CMPR transitions away from 3YMA-based PSUs company-wide.
Appendix: Committee Summary (FY2025)
| Committee | Role | Meetings | Independence |
|---|---|---|---|
| Audit | Member | 5 | Yes; meets audit independence criteria |
| Compensation | Member | 4 | Yes; meets compensation independence criteria |
| Nominating | Chair | 2 | Yes |